Lexeo Therapeutics, Inc.

What they do

Lexeo develops intravenously delivered AAVrh10-based gene therapy candidates for inherited heart conditions. Its lead program, LX2006, targets Friedreich ataxia cardiomyopathy by delivering a functional frataxin (FXN) gene, and is in Phase 1/2 and a pivotal study. Its second program, LX2020, delivers a functional PKP2 gene for PKP2 arrhythmogenic cardiomyopathy. The company retains exclusive worldwide development and commercialization rights to its programs.

Revenue drivers

• LX2006 (FA cardiomyopathy) — Lead product candidate in Phase 1/2 and the SUNRISE-FA 2 pivotal study; no product revenue to date, and the company reported only $654,000 of annual revenue in 2022.
• LX2020 (PKP2-ACM) — Second most advanced candidate in the HEROIC-PKP2 Phase 1/2 trial; received RMAT designation in August 2026; no revenue generated.
• Preclinical assets (e.g., LX2022) — Early-stage programs such as LX2022 for TNNI3 gene replacement in hypertrophic cardiomyopathy; preclinical only and not a current revenue source.

Recent performance

Lexeo has no product revenue; annual net losses widened from $59.3M in 2022 to $100.0M in 2025, with operating cash use of $98.6M in 2025. As of June 30, 2026, total assets were $254.9M, liabilities $19.8M, and shareholders' equity $235.1M. The company reported cash, cash equivalents, and investments of $234.2M at June 30, 2026, which it says funds operations into 2028. In the second quarter of 2026, Lexeo initiated the SUNRISE-FA 2 pivotal study for LX2006 and received RMAT designation for LX2020.

Strategy

Lexeo is prioritizing execution of the LX2006 pivotal program under the accelerated approval pathway, with a BLA submission targeted for the first half of 2028. It finalized the SUNRISE-FA 2 protocol and statistical analysis plan in June 2026 and continues FDA engagement on confirmatory evidence strategy. For LX2020, the company plans a 12-month data update for all high-dose participants in Q4 2026 and regulatory engagement in 2026, supported by RMAT designation. The company uses a stepwise, capital-efficient development approach and expects its $234.2M cash position to fund operations into 2028.

Risks

• Clinical and regulatory risk — LX2006 and LX2020 remain investigational, and the FDA has not approved either candidate; the confirmatory evidence strategy for SUNRISE-FA 2 is not yet finalized.
• No product revenue — The company has generated minimal revenue ($654,000 in 2022) and relies on external financing, with net losses reaching $100.0M in 2025.
• Cash runway dependence — Lexeo's stated runway into 2028 depends on its $234.2M cash, cash equivalents, and investments as of June 30, 2026, and future spending on pivotal trials.
• Manufacturing and CMC risk — The company relies on third-party manufacturing partners and AAVrh10 production, and participates in the FDA's CMC Development and Readiness Pilot to support registrational readiness.

Outlook

Management expects topline data from the SUNRISE-FA 2 pivotal study of LX2006 in the second half of 2027 and a potential BLA submission under accelerated approval in the first half of 2028. For LX2020, a 12-month data update for all high-dose participants is expected in Q4 2026, alongside regulatory engagement with the FDA in 2026. Lexeo states its cash position is sufficient to fund operations into 2028.